전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,092 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Raludotatug deruxtecan (Raludotatug deruxtecan)

Carcinoma, Non-Small-Cell Lung · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#antibody-drug-conjugate#Carcinoma+2
Trials 7Status Recruiting
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 2

anti-MUC1 CAR-T cells (anti-MUC1 CAR-T cells)

Advanced Esophageal Cancer · Malignant Glioma of Brain

#MalignantGliomaofBrain#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 7Status Active
CGTLimited DatastaleUTC Therapeutics Inc.Preclinical

Anti-HER2 CAR-T cells (Anti-HER2 CAR-T cells)

HER2-positive Advanced Malignant Solid Tumors · HER2

#HER2#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 6Status Recruiting
CGTLimited DatastaleStephan Grupp MD PhDPhase 2

CART22-65s (Autologous, humanized anti-CD22 CAR T cell therapy, Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s))

B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma · CD22

#CD22#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 6Status Recruiting
CGTLimited DatastaleShanghai AbelZeta Ltd.Phase 1

C-CAR-011 (C-CAR-011)

Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Active
CGTLimited DatastaleCity of Hope Medical CenterPhase 2

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes)

Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 6Status Recruiting
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Lenzilumab (Lenzilumab)

Relapsed/Refractory Large B-cell Lymphoma · FRα

#FR#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 6Status Discontinued
ADCLimited DatastaleMing-Yuan ChenPhase 3

Neoadjuvant and Adjuvant Becotatug Vedotin (Neoadjuvant and Adjuvant Becotatug Vedotin)

Locally Advanced Head and Neck Squamous Cell Carcinoma · Locally Advanced Head and Neck Squamous

#LocallyAdvancedHeadandNeckSquamo#ADC#Phase3#antibody-drug-conjugate#Ming-Yuan
Trials 6Status Recruiting
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 2

T cell injection targeting CD7 chimeric antigen receptor (T cell injection targeting CD7 chimeric antigen receptor)

CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 6Status Recruiting
CGTLimited DatastaleTILT Biotherapeutics Ltd.Phase 2

TILT-123 (TILT-123)

Melanoma; Head and Neck Squamous Cell Carcinoma · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 6Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

anti-CD5 CAR T cells (anti-CD5 CAR T cells)

T-cell Acute Lymphoblastic Leukemia; T-cell Non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Active
CGTLimited DatastaleGenethonPhase 2

Autologous CD34+ cells transduced with WASP lentiviral vector (Autologous CD34+ cells transduced with WASP lentiviral vector)

Wiskott-Aldrich Syndrome · CD3

#CD3#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 5Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

BCMA-CD19 cCAR T cells (BCMA-CD19 cCAR T cells)

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 5Status Recruiting
AntibodyLimited DatastaleAravive, Inc.Phase 2

Batiraxcept (Batiraxcept)

Clear Cell Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma

#ClearCellRenalCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Aravive
Trials 5Status Discontinued
AntibodyLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Boserolimab (Boserolimab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#monoclonal-antibody#Carcinoma+2
Trials 5Status Recruiting
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

CART22 cells (CART22 cells)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 5Status Discontinued
CGTLimited DatastaleGuangdong Ruishun Biotech Co., …Phase 1

CD19-CAR-DNT cells (CD19-CAR-DNT cells)

B-cell Non-Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 5Status Active
CGTLimited DatastaleTakedaPhase 1

CD19-CAR-T2 Cells (CD19-CAR-T2 Cells)

Acute Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 5Status Active
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy (Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 5Status Discontinued
CGTLimited DatastaleEssen BiotechPhase 1

Mesothelin-directed CAR-T cells (Mesothelin-directed CAR-T cells)

Solid Tumor, Adult · Solid Tumor, Adult

#SolidTumorAdult#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 5Status Active

12 / 55 pages

← PreviousNext →